Sign In
Buy SLS
$8.23
-0.81 (-8.96%)
At Close: Jun 05, 2026
The Common Cancer-associated Antigens (CAAs) Vaccine research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and
Cantor Fitzgerald Trims SELLAS Life Sciences Group (NASDAQ:SLS) Target Price to $16.00
08:24am, Monday, 06'th Dec 2021 Dakota Financial News
SELLAS Life Sciences Group (NASDAQ:SLS) had its price target reduced by Cantor Fitzgerald from $18.00 to $16.00 in a report issued on Friday, The Fly reports. They currently have an overweight rating on the stock. Several other research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of SELLAS Life Sciences Group []
Price T Rowe Associates Inc. MD Sells 11,600 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)
09:36am, Sunday, 05'th Dec 2021 Dakota Financial News
Price T Rowe Associates Inc. MD lessened its holdings in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 42.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,500 shares of the companys stock after selling 11,600 shares during the []
SELLAS Life Sciences Announces Final Court Approval of Settlement of Derivative Litigation
01:30pm, Tuesday, 23'rd Nov 2021 GlobeNewswire Inc.
Claims in Derivative Suits Related to Activities of SELLAS’ Predecessor, Galena Biopharma, Inc. Claims in Derivative Suits Related to Activities of SELLAS’ Predecessor, Galena Biopharma, Inc.
SELLAS Life Sciences Announces Final Court Approval of Settlement of Derivative Litigation
01:30pm, Tuesday, 23'rd Nov 2021 Intrado Digital Media
Claims in Derivative Suits Related to Activities of SELLAS Predecessor, Galena Biopharma, Inc. Claims in Derivative Suits Related to Activities of SELLAS Predecessor, Galena Biopharma, Inc.
SELLAS Life Sciences Group (NASDAQ:SLS) Posts Quarterly Earnings Results, Misses Expectations By $0.09 EPS
01:28pm, Monday, 15'th Nov 2021 Dakota Financial News
SELLAS Life Sciences Group (NASDAQ:SLS) released its quarterly earnings data on Friday. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.09), MarketWatch Earnings reports. NASDAQ SLS opened at $7.18 on Monday. SELLAS Life Sciences Group has a 12 month low of $2.47 and a 12 month high of []
SELLAS Life Sciences to Participate in Upcoming Conferences in October 2021
09:14am, Thursday, 07'th Oct 2021
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel
SELLAS Life Sciences Announces Settlement of Derivative Litigation
04:05pm, Thursday, 23'rd Sep 2021
NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel
SELLAS Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 28th
08:30am, Tuesday, 14'th Sep 2021
NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel
SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
04:22pm, Thursday, 12'th Aug 2021
Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advanced Ovarian Cance
Sellas Life Sciences Breaks Out Of Pennant Pattern: Technical Levels To Watch
02:49pm, Wednesday, 30'th Jun 2021
SELLAS Life Sciences Group Inc. (NASDAQ: SLS) shares were trading lower Wednesday after the company released updated clinical and initial immunobiological data from a Phase 1/2 clinical trial ofits
Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up
SELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo
08:30am, Thursday, 24'th Jun 2021
Updated Data Show Median Overall Survival of 35.4 Weeks in Patients Treated With Combination Therapy for at Least One Month – Median Overall Survival in Relapse/Refractory Patients with Standard of
SELLAS Life Sciences Announces Inclusion in Russell Microcap® Index
09:05am, Tuesday, 22'nd Jun 2021
NEW YORK, June 22, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel
Sellas Life Sciences Stock May Have Broken Out Of Pennant Pattern: What's Next?
06:11pm, Tuesday, 01'st Jun 2021
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) shares rallied Tuesday as retail traders try to push the stock higher. The stock is likely continuing its momentum after the company secured a U.S. patent
